Healios KK Ord Shs HLOSF

Healthcare Biotechnology

Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.

PINL:HLOSF - Post by User

Healios KK Ord Shs > MD & A and Interim Financials Out

<< Previous

Bullboard Posts

Next >>

Comment by The300on Apr 20, 2011 10:10am

179 Views

Post# 18460138

RE: RE: RE: RE: MD & A and Interim Financials Out

Hey Camaroni,

I was actually thinking the same thing in terms of averaging down. Halo's cash value alone is worth .15 / share ($4,200,000 / 28,000,000 shares), so you are buying the assets for about $.17 share (based on $.32 stock price).

The only thing that prevents me from buying more at this point is the lack of communication and marketing coming from the company.

Regards,

The 300

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec